Renaissance Technologies LLC Grows Stake in Omada Health, Inc. $OMDA

Key Points

• Renaissance Technologies increased its Omada Health stake by 173.9% in the first quarter, bringing its holdings to 391,069 shares valued at approximately $4.9 million, or 0.66% of the company.
• Omada reported stronger-than-expected quarterly results and continued growth: EPS was $0.08 versus a consensus loss of $0.02, revenue rose 43% year over year, and membership increased 45%. Full-year revenue guidance of $334 million to $340 million exceeded analyst expectations.
• Analysts remain broadly positive, but insider selling and a planned CEO transition add considerations. The stock has a “Moderate Buy” consensus rating with a $24.75 target price, while insiders sold more than $4.1 million in shares over the past 90 days and CEO Sean Duffy is set to become executive chair in 2027.

Renaissance Technologies LLC increased its stake in shares of Omada Health, Inc. (NASDAQ:OMDA - Free Report) by 173.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 391,069 shares of the company's stock after purchasing an additional 248,269 shares during the period. Renaissance Technologies LLC owned 0.66% of Omada Health worth $4,916,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of Omada Health during the 2nd quarter worth approximately $32,000. Bellevue Group AG grew its stake in shares of Omada Health by 0.7% in the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company's stock valued at $5,567,000 after buying an additional 1,791 shares during the period. Quarry LP acquired a new stake in shares of Omada Health during the 4th quarter worth approximately $29,000. Barclays PLC increased its holdings in shares of Omada Health by 14.6% during the 4th quarter. Barclays PLC now owns 14,850 shares of the company's stock worth $234,000 after buying an additional 1,888 shares during the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in shares of Omada Health during the 4th quarter valued at approximately $32,000.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Quarterly results beat expectations. Omada reported adjusted earnings of $0.15 per share, up from a $0.09 loss a year earlier and above the $0.05 consensus estimate. Another earnings summary reported EPS of $0.08 versus an expected loss of $0.02, reinforcing that results exceeded forecasts. Omada Health Q2 earnings and revenues top estimates
• Positive Sentiment: Growth remained strong. Second-quarter revenue rose 43% year over year, while total members increased 45%. Gross margin also reached a new quarterly record, supporting the company’s growth and profitability narrative. Omada Health reports second-quarter 2026 results
• Positive Sentiment: Full-year revenue guidance exceeded Wall Street expectations. Omada forecast fiscal 2026 revenue of $334 million to $340 million, above the $327.2 million analyst consensus. This suggests management expects sustained demand for its digital chronic-care programs.
• Neutral Sentiment: Leadership transition adds an execution consideration. Co-founder and CEO Sean Duffy will become executive chair on January 1, 2027, while President Wei-Li Shao becomes CEO. The planned, internal succession may provide continuity, although investors will monitor whether the change affects growth execution.
• Negative Sentiment: CEO insider selling provided a modest counterpoint. Duffy sold 12,944 shares for approximately $264,000, reducing his direct ownership by 3.05%. While the sale may have been for personal or financial-planning reasons, insider selling can weigh on sentiment.

Analyst Ratings Changes

Several research firms have issued reports on OMDA. Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of Omada Health in a research note on Friday, May 8th. Evercore reiterated an "outperform" rating and set a $20.00 price target on shares of Omada Health in a report on Friday, May 8th. Citigroup reissued an "outperform" rating on shares of Omada Health in a research report on Monday, July 20th. Wells Fargo & Company upped their target price on shares of Omada Health from $17.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 8th. Finally, Canaccord Genuity Group lifted their price target on shares of Omada Health from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Tuesday, July 21st. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Omada Health has a consensus rating of "Moderate Buy" and a consensus target price of $24.75.

Insider Buying and Selling

In other Omada Health news, CFO Steven L. Cook sold 33,000 shares of the business's stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $19.89, for a total transaction of $656,370.00. Following the completion of the transaction, the chief financial officer owned 133,359 shares in the company, valued at $2,652,510.51. The trade was a 19.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Craig Gracey sold 6,894 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $17.42, for a total transaction of $120,093.48. Following the completion of the sale, the chief accounting officer directly owned 9,191 shares in the company, valued at approximately $160,107.22. This represents a 42.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 206,406 shares of company stock worth $4,191,483 over the last 90 days. 6.38% of the stock is owned by insiders.

Omada Health Price Performance

Shares of NASDAQ OMDA opened at $19.54 on Friday. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -72.37 and a beta of 1.73. The stock's 50-day moving average is $20.24 and its two-hundred day moving average is $16.15. Omada Health, Inc. has a 1-year low of $10.28 and a 1-year high of $26.92.

Omada Health (NASDAQ:OMDA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.10. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. Equities research analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Omada Health Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

Want to see what other hedge funds are holding OMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omada Health, Inc. (NASDAQ:OMDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source